Aging 2 , 6073 (2022)
GLP-1 weight loss creates tissue characteristics that differ from those seen after bariatric surgery or traditional dieting
Long-term urinary health on GLP-1 therapy Most discussions about semaglutide and UTIs focus on the short-term risks
By 48 weeks, significant average weight loss was seen at all maintenance doses: With longer treatment lasting up to 68 weeks, weight loss continued, particularly at higher doses: 12mg: average weight loss of up to 28.7% of body weight This longer-term data shows that weight loss with retatrutide can continue beyond one year, rather than plateauing early, especially at higher maintenance doses
In reality, treatment decisions are much more individualized
Contrastingly, in coma, deep tendon reflexes can decrease, and even disappear.28 In patients with ALF, the development of HE is a rapidly progressing process of cognitive decline and abrupt confusion, with limb rigidity and resistance to passive movements
